NewsBenzingaGuggenheim lance la couverture d’Ovid Therapeutics avec une recommandation d’achat et annonce un objectif de cours de 7 $ Guggenheim lance la couverture d’Ovid Therapeutics avec une recommandation d’achat et annonce un objectif de cours de 7 $ Benzinga 2026.10.05 20:16 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Parker Hannifin Stock In The Last 5 Years Backpack Launches Cerebras Tokenized Stock CBRS on Solana, Redeemable 1:1 for Shares Elon Musk is a Trillionaire Again Thanks to SpaceX Stock DeFi Development Corp Adds $3 Million in Solana as SOL Buys Slow $1000 Invested In Tenet Healthcare 15 Years Ago Would Be Worth This Much Today This new AI model could help America close a technological gap with China
